Cardiogenomics Pte Ltd is a local start-up and Singapore’s first Cardiac Genomics company.
Cardiogenomics’ genetic tests were developed by NUS/NUH researchers. Our tests allow the genetic diagnosis of vulnerabilities to Inherited Cardiac Diseases and to assess and control the individual risk of Coronary Artery Disease.
Professor Heng graduated with a PhD in Human Genetics from the National University of Singapore in 1996. He is an Associate Professor and Research Director with the Department of Paediatrics, Yong Loo Lin School of Medicine, NUS. In 1997, Professor Heng received an exchange scholarship from the University of Pittsburgh for his molecular genetics training in the Department of Human Genetics. Subsequently, he was trained in genetic epidemiology at the Johns Hopkins University’s School of Public Health in 2000. Professor Heng’s research interests are in cardiovascular genetics. He has over 27 years of R&D experience.
To-date, he has authored and published more than 90 scientific papers in peer-reviewed journals and filed 8 patents related to diagnostics tools.
Roger Foo is an Associate Professor at the Department of Medicine, National University of Singapore (NUS), Senior Consultant at the National University Heart Centre (NUHCS), and the Consultant lead who established and runs the Cardiac Genetics clinic at NUH. He is a graduate of the Medical School at NUS, but spent 20 years overseas before returning to Singapore in 2013. He first undertook post-graduate specialist training at Kings College Hospital in London, followed by Addenbrooke’s Hospital in Cambridge.
In 2003, he was awarded the UK Wellcome Trust Fellowship to pursue post-doctoral research at the Albert Einstein College of Medicine in New York. He then returned to the University of Cambridge as a British Heart Foundation Fellow and Consultant Physician, till his return to Singapore. His lab was the first to publish an epigenomic map of the failing human heart in 2012. More recently, his lab has found a long intergenic noncoding RNA, naming it Singheart, which potentially holds the key for the heart to self-heal. The lab’s projects now dive deep into the epigenome of heart failure, using advanced technology such as single cell transcriptomics and Crispr-genome editing to explore new frontiers in cardiovascular biology, with the continuing aspiration of discovering novel avenues for therapeutic or biomarker development.
Today, his research laboratory is based at NUS and the Genome Institute of Singapore, and is supported by grants from the Singapore National Medical Research Council and the Biomedical Research Council. He is also a strong advocate for the clinical application of genomics and most recently, he is leading the BMRC Rare Disease research programme called SUREkids. SUREkids aims to develop a clinical pipeline for whole exome sequencing for babies at both Paediatric Genetics departments in Singapore.
Over 18 years of experience in Start-up Enterprises, Commercial Development, Science Liaison and R&D as well as Project and Clinical Trial Management in multinational and multicultural environments (APAC, Japan, USA and Europe).
More than 20 years of experience in building business relationships, business development, commercial development and working with Venture Capitalists on high-level strategy.